CHERYL GISTAND: Open Payments
NPI 1922560440 · VINCENNES, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$269 in 13 payments from 10 companies in 2025. Trend: 2023 $164 · 2024 $190 · 2025 $269
Food & beverage: $269
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Biogen, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Alkermes, Inc. | 1 | $14 |
Products named: FANAPT, Auvelity, ZURZUVAE, AUSTEDO XR, INGREZZA, SUBLOCADE, CAPLYTA, INVEGA SUSTENNA.
Industry payments across IN — which companies pay providers there.
